Ļ

1			
2	01 JUL 19 AH 10: 47		
3	CLERK, U.S. DIN TOTO CURT		
4	Dally in the second		
5	" Contract and		
6	•		Ì
7			
8	UNITED STATES DISTRICT COURT		
9	SOUTHERN DISTRICT OF CALIFORNIA		
10			
11	GEN-PROBE INCORPORATED,	ł	CASE NO. 99-CV- 2668 H (AJB)
12		Plaintiff,	Order Denying Motion for Entry of Final Judgment under Rule 54(b)
13	<b>VS</b> ,		FIRE Jungment under Kult Se(P)
14	VYSIS, INC.,		
15	Defendant		
16			
17	On June 19, 2001, the Court granted plaintiff Gen-Probe's motion for partial summary		
18	judgment that its nucleic acid test for human immunodeficiency virus ("HIV") and hepatitis C virus		
19	("HCV") does not literally infringe the claims of defendant Vysis' U.S. Patent No. 5,750,338 ("the		
20	'338 patent"). The Court construed the term "amplifying" as found in the '338 patent as encompassing		
21	only non-specific amplification methods.		
22	On June 29, 2001, Vysis filed a Motion for Entry of Final Judgment under Rule 54(b) of the		
	8		

Federal Rules of Civil Procedure. The parties agreed to an expedited briefing schedule on the motion.
Gen-Probe filed an Opposition on July 10, 2001 and Vysis filed a Reply on July 13, 2001. The motion
is submitted on the papers without oral argument pursuant to Local Rule 7.1(d)(1).

Vysis seeks entry of final judgment against it on Counts I and III of Gen-Probe's Second Aniended Complaint pursuant to Rule 54(b) and a stay of all remaining proceedings so that it may pursue an immediate appeal to the Federal Circuit. Count I of the Second Amended Complaint alleges



99cv2668

•.`

1 that Gen-Probe's HIV and HCV test kits do not infringe the claims of the '338 patent. Count III asks
2 for a declaration of Gen-Probe's rights and obligations under its license with Vysis.

Gen-Probe asserts that the Court's grant of partial summary judgment does not completely 3 resolve Count I because the Court did not address infringement under the doctrine of equivalents. In 4 its Reply, Vysis stipulates that if the Court enters final judgment under Rule 54(b), it will not assert 5 that Gen-Prohe's HIV/HCV test infringe under the doctrine of equivalents unless the Court's claim 6 construction is reversed or modified. Vysis also states that should the Federal Circuit affirm the 7 Court's claim construction, it will not later assert that Gen-Probe's HIV/HCV test kits infringe the 8 claims of the '338 patent under the doctrine of equivalents. Nonetheless, the Court declines to direct 9 entry of final judgment as to Count I of the Second Amended Complaint." 10

Rule 54(b) of the Federal Rules of Civil Procedure gives courts the discretion to direct the 11 entry of a final judgment as to one or more of the claims in a case upon the express determination that 12 there is no just reason for delay. A district court may grant Rule 54(b) certification if it will aid 13 "expeditious decision" of the case. Texaco. Inc. y. Ponsoldt, 939 F.2d 794, 798 (9th Cir. 1991) 14 (quoting Sheehan v. Atlanta Int'l Ins. Co., 812 F.2d 465, 468 (9th Cir. 1987)).<sup>1</sup> However, Rule 54(b) 15 certification is inappropriate when it allows "piecemeal appeals in cases which should be reviewed 16 only as single units." Id. (citations omitted). Partial judgments under Rule 54(b) are reserved for cases 17 where "the costs and risks of multiplying the number of proceedings and of overcrowding the appellate 18 docket" are outweighed by the pressing need for an early and separate judgment. Morrison-Knudsen 19 Co. v. Archer, 655 F.2d 962, 965 (9th Cir. 1981). Partial judgment under Rule 54(b) is proper where 20 there are distinct claims and immediate review of the portions ruled upon will not result in later 21 duplicative proceedings in the trial or appellate court. White Mountain Apache Tribe v. Hodel, 784 22

- 23
- 24
- 25 The Court also declines to direct entry of final judgment as to Count III of the Second Amended Complaint. In Count III, Gen-Probe seeks a declaration of its rights and obligations under the '338 patent in light of its noninfringement and invalidity challenges. Because the Court has not addressed the invalidity challenges to the '338 patent, Count III is not eligible for Rule 54(b) certification.
- 27 27 The Federal Circuit applies the law of the regional circuit when evaluating a procedural issue, like Rule 54(b)
   28 certification, that is not related to patent law. <u>CAE Screenplates Inc. v. Heinrichfielder CimbH & Cu.</u>, 224 F.3d 1308, 1314-15 (Fed. Cir. 2000).

- 2 -

91cv2668

costeres de tere

1

Ð

U

ų

Ĉ

Ō â

Ċ

FU. 18

19

20

21

22

F.2d 921,923-24 (9th Cir. 1986); Morrison-Knudsen, 655 P.2d at 965. "A similarity of legal or factual issues will weigh heavily against entry of judgment [under Rule 54(b)]." Morrison-Knudsen, 655 F.2d 2 at 965. 3

The Court's grant of partial summary judgment does not determine whether the '338 putent 4 is valid. Counts Two, Three, Four, Five, and Six of Gen-Probe's Second Amended Complaint each 5 assert that the '338 patent is invalid. Gen-Probe continues to prosecute those causes of action. Vysis 6 argues that these Counts are separable from Count One and that failure to obtain a prompt 7 determination of the scope of the claims may result in an unnecessary delay in determining Gen-8 Probe's obligation to pay royalties under the '338 patent license agreement with Vysis. Vysis asks 9 for a stay of the proceedings on Gen-Probe's remaining counts until after appeal to the Federal Circuit. 10 In this case, an interlocutory appeal is not the quickest path to a final and complete resolution 11 of the case. A pre-trial conference has been set in this case for January 14, 2002. At trial, all of the 12 issues in the case can be disposed of and a full factual record can be developed. Entry of final 13 judgment of Count One, when the invalidity issues remain pending, would result in an incllicient use 14 of judicial resources and unnecessary delay in the ultimate resolution of this case. 15

Consequently, the Court DENIES Vysis Motion for Entry of Final Judgment Under Rule 54(b). 16 IT IS SO ORDERED. 17

- 3 -

Chief Indge

UNITED STATES DISTRICT COURT

23 Copies to:

DATED:

24 Slephen Swinton Coolcy Godward LLP 4365 Executive Drive, Suite 1100 25 San Diego, CA 92121

26 Charles Lipscy Pinnegan, Hondomon, Farabow, Garrett & Dunner 27 1300 I Street, N.W., Suite 700 28 Washington, D.C. 20005

1-18-0